We have filed over a dozen patent applications on groups of novel chemical entities as of late 2023, with the earliest beginning to convert into awarded patents. And we continue to make new discoveries. Our IP includes molecules, drug combinations, treatment methods, and pharmaceutical preparations. These primarily focus on the goal of enabling safer, gentler take-home prescription mental health medicines. We believe this will be a key to effective and accessible mental wellness for millions of people.
Because we focus on gentler molecules, we are necessarily discovering new molecules outside this area of focus that possess therapeutic promise. When these molecules offer potential significant advantages over available options, we evaluate developing them, potentially in partnership with other organizations.